The results of three lung cancer-related clinical trials showed that artesunate combined with chemotherapy upregulated the CD39, CD279, and GrzB expression in CD8+ and CD4+ T cells in patients with lung cancer, thereby modulating the immune function of T-cell subsets. The gene discussed is CD8A; the disease is lung carcinoma.